Short report
Autosomal recessive chondrodysplasia with severe short stature caused by a biallelic COL10A1 variant AbsTrACT background heterozygous mutations in COL10A1 underlie metaphyseal chondrodysplasia, Schmid type (MCDS), an autosomal dominant skeletal dysplasia. Objective to identify the causative variant in a large consanguineous pakistani family with severe skeletal dysplasia and marked lower limb deformity. Methods Whole exome sequencing was completed followed by Sanger sequencing to verify segregation of the identified variants. In silico variant pathogenicity predictions and amino acid conservation analyses were performed. results A homozygous c.133 C>t (p.pro45Ser) variant was identified in COL10A1 in all six severely affected individuals (adult heights 119-130 cm, mean ~−6.33 SD). the individuals heterozygous for the variant had mild phenotype of short stature (adult heights 140-162 cm, mean ~−2.15 SD) but no apparent skeletal deformities. the variant was predicted to be pathogenic by in silico prediction tools and was absent from public databases and hundred control chromosomes. pro45 is conserved in orthologues and is located in the non-collagenous 2 domain of CoL10A1, variants of which have never been associated with skeletal dysplasia. Conclusions this first report of individuals with a homozygous variant in COL10A1 defines a new type of autosomal recessive skeletal dysplasia. the observations in COL10A1 variant carriers suggest a phenotypic overlap between the mildest forms of MCDS and idiopathic short stature.
INTrOduCTION
Metaphyseal chondrodysplasia, Schmid type (MCDS; OMIM 156500) is an autosomal dominant disorder. It is characterised by short stature, long bone deformities such as genua vara and coxa vara, and radiographic signs of metaphyseal dysplasia. Fifty heterozygous mutations in COL10A1 encoding type X collagen have been reported to cause MCDS (Human Gene Mutation Database; http://www. hgmd. cf. ac. uk/ ac, accessed June 2017). Type X collagen is a homotrimer non-fibrillar collagen, composed of three alpha-1(X) chains of 680 amino acids. It is present in the extracellular matrix and is exclusively produced by the hypertrophic chondrocytes during the endochondral ossification. 1 The protein plays a role in distribution of proteoglycans and vesicles in bone matrix. COL10A1 is comprised of a signal peptide (amino acids [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] at the N-terminal followed by a non-collagenous 2 (NC2) region (19-56), a triple helical region (57-519) and a non-collagenous 1 (NC1) region (520-680) at the C-terminal. 1 All except three mutations 2 3 known to cause MCDS affect the NC1 region. Haploinsufficiency is one of the proposed mechanisms for the disorder since a 50% reduction of COL10A1 is observed in bone cartilage of patients with MCDS who are heterozygous for some non-sense and frameshift mutations. 4 5 Dominant-negative effects of COL10A1 non-sense and mis-sense variants have also been shown to be responsible for causing the disorder. 6 The NC1 region contains motifs required for trimerisation of COL10A1 and a loss of NC1 leads to improper trimerisation of collagen, 7 resulting in accumulation of these misfolded proteins in the cells. This leads to endoplasmic stress and apoptosis in hypertrophic chondrocytes during endochondral ossification. 8 9 However, mutations that result in a change of amino acid at the exterior of NC1 region (p.Asp617Lys and p.Gly618Val) allow trimerisation but hinder supramolecular assembly and interaction of COL10A1 with endoplasmic reticulum and proteins in extracellular matrix. 10 11 In addition, mutations of residues which introduce a charge deep inside the hydrophobic NC1 domain affect the trimerisation process and produce unstable COL10A1 which is degraded in the endoplasmic reticulum 8 resulting in haploinsufficiency. Some NC1 mis-sense variants, for example (p.Tyr598Asp), have been demonstrated to give rise to formation of abnormal disulfide bonds by exposing sulfhydryl groups of cysteine which are normally buried inside protein in the normal configuration. 8 To date, all patients reported with pathogenic variants in COL10A1 have been heterozygous. In the present study, we describe a large consanguineous family with a novel mis-sense variant of COL10A1 leading to a pronounced phenotype with severe short stature and lower limb deformities in homozygous individuals while family members harbouring a heterozygous variant were only mildly affected. This is the first disease-causing variant in COL10A1 located in the NC2 domain of the protein. Further, to the best of our knowledge, this is the first report of individuals with a homozygous variant in COL10A1.
MATerIAls ANd MeThOds Patients
The study was approved by the Institutional Review Board at the School of Biological Sciences, University of the Punjab, Lahore, Pakistan. Family NAD-02 ( figure 1A ) was recruited to the study after New disease loci obtaining written informed consents from the participants or their parents. A detailed history about the onset and progression of growth failure and deformities was obtained. Family history was recorded and photographs were taken. Ages and heights of all family members were recorded and SD scores for heights were calculated using WHO population-based reference values. Medical radiographs could not be obtained as all family members refused the testing. Peripheral blood samples were drawn from the participants. DNA was isolated using a standard protocol.
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Molecular analysis
Whole exome sequencing (WES) was performed for one severely affected individual IV:15 using Agilent V4 enrichment kit (Agilent Technologies, Santa Clara, CA). Paired-end reads were obtained at 50× coverage on an Illumina Hi-Seq 2000 sequencer (Otogenetics, Norcross, GA). Reads were mapped to UCSC hg19 reference human genome (http:// genome. ucsc. edu/). The web-based program wANNOVAR was used for further annotating variants. All heterozygous variants and variants in dbSNP database, Exome Aggregation Consortium, 1000 Genomes and in 6500 exon sequence project with minor allele frequency greater than 0.0099 were removed. Exonic and splice site variants were considered. Homozygous chromosomal intervals in the exome data were identified using Agile Variant Mapper and intronic and synonymous variants located in these regions were also scrutinised. The disease-causing potential of sorted variants was checked by using online prediction programs which included Polyphen2, MutationTaster, Mutation Assessor and fathmm. Clustal Omega was used for generating protein alignment of COL10A1 orthologous sequences retrieved from UCSC genome browser. Primers for the amplification of genomic regions containing the selected variants were designed using Primer3. The segregation of each variant with the phenotype was checked after PCR amplification of the specific product 
resulTs
Clinical features
Family NAD-02 had eight severely affected individuals born in four consanguineous marriages ( figure 1A) . Six affected individuals participated in the study. All severely affected individuals had severe disproportionate short stature with short limbs and significant lower limb varus or valgus deformity but normal facial features (table 1) . Their growth was reported to be normal until the age of 6 years. However, no longitudinal height data were available. The adult heights ranged from 114 to 130 cm (table 1) . Lower limb deformities progressed with age in all, with older individuals complaining of joint pain in knees. None of the patients had significant scoliosis. Bowing of legs was visible but hands and feet were normal. One individual (IV:2) homozygous for the variant had genu valgum while all other severely affected individuals had genu varus. Apart from the skeletal findings, no other clinical signs, including intellectual disability, infections, respiratory problems or hearing deficits, were present in any of the affected individuals. Family members who were obligate carriers and those who were subsequently found to be heterozygous for the disease-causing variant were apparently normal but had mild short statures (adult heights from 140 to 162 cm) (table 1). They did not complain of joint pain or other health-related issues. None of these individuals considered themselves as affected.
Molecular findings
Analysis of the WES data revealed a novel homozygous mis-sense mutation in exon 2 of COL10A1, c.133 C>T (p.Pro45Ser) which fully cosegregated with the disease phenotype in the family, with the six severely affected individuals being homozygous for the variant ( figure 1A ,B, see online supplementary table 1). Analysis of data for individual 1V:15 indicated that all coding exons located in the homozygous chromosome 6 interval (114-130 MB, according to GRCh37/hg19, data not shown), in which COL10A1 is located, were fully covered by exome sequencing. No other potential pathogenic variant was identified in the exome data within this region of homozygosity on chromosome 6 and none of the other variants on different chromosomal intervals segregated with the phenotype (see online supplementary table 1).
The COL10A1, c.133 C>T (p.Pro45Ser) mutation was absent from public databases including gnomAD (http:// gnomad. broadinstitute. org/) as well as in ethnically matched 100 control chromosomes. The variant was predicted to be pathogenic or damaging by all four prediction programs and also had a high Combined Annotation Dependent Depletion score of 14.55 (see online supplementary table 1). The Pro45 amino acid is absolutely conserved in COL10A1 orthologues ( figure 1C ).
dIsCussION
Variants of COL10A1 have been shown to cause MCDS in humans and chondrodysplasia in mice. Both haploinsufficiency and dominant-negative gain of function are proposed mechanisms for MCDS. Here we describe a new form of skeletal dysplasia caused by biallelic mutations in COL10A1 resulting in a skeletal phenotype which is reminiscent of MCDS caused by heterozygous COL10A1 variants but with more severe symptoms. Interestingly, the carriers of (p.Pro45Ser) variant had mild short statures but no other phenotypic manifestations. One explanation for this variant causing the severe manifestations of the disorder only in the homozygous form could be due to the unusual site of the mutation ( figure 1D ). The variant identified in the present family is located in the NC2 region of COL10A1, in which no pathogenic variants have been identified previously. All reported dominantly inherited mutations in patients with MCDS are located in the NC1 region of COL10A1 except for three variants. 2 3 These COL10A1 heterozygous variants affect the signal peptide (p.Gly18Arg), (p.Gly18Glu) or the triple helical domain (p.Gly288Arg) of COL10A1 ( figure 1D, see online supplementary table 2) . The three variants are associated with late onset and mild forms of MCDS. 2 3 All except one (p.Val677Glu) of the pathogenic variants of NC1 region of COL10A1 (figure 1D and online supplementary table 2) result in the development of a severe form of the disease. The NC1 domain has been shown to play a vital role in the trimerisation of collagen X. 7 Moreover, it has been proposed that the NC1 region interacts with other proteins and any alteration in the NC1 region may also lead to accumulation of its interacting proteins inside cells, adding to pathology of disease. 
New disease loci
Homozygous Col10a1 -/-null mutant mice exhibit late-onset extremely mild abnormalities.
14 These mutant mice develop unilateral coxa vara on ageing. The observed difference in the severity of phenotype between mice and humans was proposed to be due to the difference in the weight borne by growth plates in both species.
14 However, transgenic wild-type mice transfected with mutant COL10A1 develop a severe phenotype with genu valgum, coxa vara and short stature similar to that found in human patients with MCDS heterozygous for these mutations. 15 16 The severity of the disease in these mice is gene dosage dependent with homozygous mutant mice being more severely affected than their heterozygous littermates. 15 16 We speculate that the (p.Pro45Ser) variant causes the disease in a dosage-dependent manner similar to that seen for transgenic mice with COL10A1 mutations.
The lack of radiographs for the participants in our study hinders an unequivocal phenotypic diagnosis for both individuals heterozygous and homozygous for the variant. Nevertheless, the variant (p.Pro45Ser) in the present family results in a later onset (at around 6 years of age) of an extremely severe disorder only in individuals carrying the homozygous variant. The usual age of onset in dominantly inherited MCDS is between 1 and 4 years. 17 It has been speculated that late onset of the disease associates with mutations leading to complete non-sense-mediated RNA decay of the mutated transcripts, while the more common early-onset forms are caused by mutations with incomplete non-sense-mediated decay and dominant-negative impairment of protein folding, endoplasmic reticulum stress response and altered hypertrophic chondrocyte differentiation. 18 The heterozygous carriers of the (p.Pro45Ser) variant had short heights, but did not exhibit apparent skeletal anomalies or other associated clinical features observed in those with dominantly inherited MCDS or in the homozygous affected individuals in their own family. Although we cannot exclude the possibility of a skeletal phenotype detectable by radiography in heterozygous individuals with (p.Pro45Ser) variant, the absence of visible skeletal defects in these individuals suggests variants in COL10A1 are attractive candidates for idiopathic short stature. The phenotypic variability among patients harbouring different COL10A1 mutations also indicates complexity in the disease mechanism.
The pathogenic mechanism through which the mis-sense variant (p.Pro45Ser) leads to severe short stature in our patients remains to be elucidated. The crystal structure for NC2 domain of COL10A1 is not available, thus precluding prediction of the potential effects of the variant on the protein. However, proline has unusual properties since it is a cyclic α-imino acid rather than an α-amino acid. Unlike other amino acids, the α-carbon atom is part of a cyclic pyrrolidine ring, which is thus introduced into the polypeptide backbone on incorporation of proline. 19 Moreover, there is no hydrogen bond donor in the amide bond. Incorporation of proline produces bends and its inclusion can serve as a helix breaker in the polypeptides. Additionally, though usually found in the cis state, it has been proposed that proline residues may act as molecular switches in mature proteins by transitioning between the cis and trans states. 20 The substitution of serine residue at position 45 may affect some of these unique properties conferred by proline. In addition, serine is an amino acid with a hydrogen bond donor. This may affect the bonding of COL10A1 or lead to its aberrant interactions with other proteins. Determination of the crystal structure of NC2 domain is required to elucidate the precise mechanism of (p.Pro45Ser) variant's effect.
The knowledge gained from in vitro and in vivo analyses of COL10A1 variants will lead to better understanding of its function in health and disease.
